Ashley Henneghan1, Andreana P Haley2, Shelli Kesler1. 1. School of Nursing; Department of Oncology, University of Texas at Austin, Austin, TX, USA. 2. Department of Psychology, College of Liberal Arts, University of Texas at Austin, Austin, TX, USA.
Abstract
OBJECTIVE: Accelerated brain aging has been proposed to explain cancer-related cognitive impairment, but empirical evidence for this relationship is lacking. The purpose of this study was to evaluate amyloid beta (Aβ) and tau, biomarkers of neurodegeneration, in relation to cognition in breast cancer survivors (BCSs). We explored relationships among peripheral concentrations of Aβ42, Aβ-40, tau, and cytokines; cognitive function; and psychosomatic symptoms in a cohort of BCSs post-chemotherapy. METHODS: This secondary analysis of a cross-sectional study was conducted with 65 BCSs. Serum total Aβ-42, Aβ-40, and tau levels were measured with single molecule array technology. Cytokines (interleukin [IL]-6, tumor necrosis factor [TNF]-α, granulocyte-macrophage colony-stimulating factor [GM-CSF], interferon [IFN]-g, IL-10, IL-12, IL-13, IL1-b, IL-2, IL-4, IL-5, IL-7, and IL-8) were simultaneously measured in serum using multiplex assays. Cognitive function was measured with five standardized neuropsychological tests and psychosomatic symptoms (stress, loneliness, anxiety, depressive symptoms, fatigue, sleep quality, and daytime sleepiness) with self-report questionnaires. Data analyses included correlations and random forest regression (RFR). RESULTS: Significant correlations were identified among hip-to-waste ratio, number of treatment modalities, Aβ-42, Aβ-40, and tau levels (rs = .27-.35, ps < .05). RFR modeling including Aβ-42, Aβ-40, tau, and cytokines as features explained significant variance in cognitive function (R 2 = .71, F = 9.01, p < .0001) and psychosomatic symptoms (R 2 = .74, F = 10.22, p < .0001). CONCLUSIONS: This study suggests that neurodegenerative biomarkers interact with cytokines to influence cognitive functioning and psychosomatic symptoms in BCSs following chemotherapy, but additional research is needed.
OBJECTIVE: Accelerated brain aging has been proposed to explain cancer-related cognitive impairment, but empirical evidence for this relationship is lacking. The purpose of this study was to evaluate amyloid beta (Aβ) and tau, biomarkers of neurodegeneration, in relation to cognition in breast cancer survivors (BCSs). We explored relationships among peripheral concentrations of Aβ42, Aβ-40, tau, and cytokines; cognitive function; and psychosomatic symptoms in a cohort of BCSs post-chemotherapy. METHODS: This secondary analysis of a cross-sectional study was conducted with 65 BCSs. Serum total Aβ-42, Aβ-40, and tau levels were measured with single molecule array technology. Cytokines (interleukin [IL]-6, tumornecrosis factor [TNF]-α, granulocyte-macrophage colony-stimulating factor [GM-CSF], interferon [IFN]-g, IL-10, IL-12, IL-13, IL1-b, IL-2, IL-4, IL-5, IL-7, and IL-8) were simultaneously measured in serum using multiplex assays. Cognitive function was measured with five standardized neuropsychological tests and psychosomatic symptoms (stress, loneliness, anxiety, depressive symptoms, fatigue, sleep quality, and daytime sleepiness) with self-report questionnaires. Data analyses included correlations and random forest regression (RFR). RESULTS: Significant correlations were identified among hip-to-waste ratio, number of treatment modalities, Aβ-42, Aβ-40, and tau levels (rs = .27-.35, ps < .05). RFR modeling including Aβ-42, Aβ-40, tau, and cytokines as features explained significant variance in cognitive function (R 2 = .71, F = 9.01, p < .0001) and psychosomatic symptoms (R 2 = .74, F = 10.22, p < .0001). CONCLUSIONS: This study suggests that neurodegenerative biomarkers interact with cytokines to influence cognitive functioning and psychosomatic symptoms in BCSs following chemotherapy, but additional research is needed.
Entities:
Keywords:
amyloid beta; breast cancer survivors; cancer-related cognitive impairment; cytokines; psychosomatic symptoms; tau
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Keely A Muscatell; Naomi I Eisenberger; Janine M Dutcher; Steven W Cole; Julienne E Bower Journal: Brain Behav Immun Date: 2015-09-15 Impact factor: 7.217
Authors: Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles Journal: Semin Oncol Date: 2013-12 Impact factor: 4.929
Authors: Yanan Zhu; Yuek Ling Chai; Saima Hilal; M Kamran Ikram; Narayanaswamy Venketasubramanian; Boon-Seng Wong; Christopher P Chen; Mitchell K P Lai Journal: Alzheimers Dement (Amst) Date: 2017-01-23
Authors: Vivian Huang; Lynda Mackin; Kord M Kober; Steven M Paul; Bruce A Cooper; Yvette P Conley; Marilyn J Hammer; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2022-09-06 Impact factor: 3.359
Authors: Ashley M Henneghan; Brandon G Fico; Michelle L Wright; Shelli R Kesler; Michelle L Harrison Journal: Explore (NY) Date: 2021-11-10 Impact factor: 2.358
Authors: Homa Pourriyahi; Niloufar Yazdanpanah; Amene Saghazadeh; Nima Rezaei Journal: Int J Environ Res Public Health Date: 2021-11-19 Impact factor: 3.390
Authors: Rebecca A Harrison; Noha Sharafeldin; Jennie L Rexer; Brennan Streck; Melissa Petersen; Ashley M Henneghan; Shelli R Kesler Journal: Oncologist Date: 2021-07-12